Which peptides are being reviewed at the July 2026 PCAC meeting?

Day one (July 23): BPC-157, KPV, TB-500, and MOTS-c. Day two (July 24): DSIP (also referred to as emideltide), Semax, and Epitalon.

Research & Educational Use Only. This article summarizes a public FDA advisory committee proceeding for informational purposes. It is not legal or medical advice, and it is not an announcement of any final FDA decision. Always verify current regulatory status directly with FDA.gov before making sourcing or compliance decisions.

Regulatory Developing Story

FDA Reviews BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon & DSIP for 503A Compounding Eligibility

Q: Does FDA review mean BPC-157 and the other peptides are now approved for compounding?

No. Being reviewed by the Pharmacy Compounding Advisory Committee (PCAC) is a step in the process, not a decision. In April 2026 the FDA removed these seven peptides from Category 2 of the 503A Bulks List, which made them eligible for PCAC review -- it did not clear them for compounding. The committee's recommendation from the July 23-24 meeting still requires FDA action before anything changes for compounders or patients.

Q: What is the 503A Bulk Drug Substances List?

It is the FDA list of bulk drug substances that licensed 503A compounding pharmacies may use to prepare compounded medications for individual patients, outside the standard new-drug approval pathway. A substance being added to (or kept off) this list directly affects whether compounding pharmacies can legally source and prepare it.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is meeting July 23-24, 2026 to evaluate whether seven research peptides qualify for the 503A Bulk Drug Substances List. This is a review step, not an approval or a ban — here's exactly what's on the table, what it means, and what it doesn't mean yet.

Update Log — checked back regularly as this develops

2026-07-23Page published ahead of Day 1 of the PCAC meeting (BPC-157, KPV, TB-500, MOTS-c on the agenda).

2026-07-23Day 1 took place as scheduled (BPC-157, KPV, TB-500, MOTS-c). FDA’s own briefing documents, published ahead of the meeting, recommended against adding any of the seven peptides to the list — citing substances that are “not well-characterized,” little or no human evidence of effectiveness for the proposed routes, and unassessed safety/immunogenicity risk. For KPV, TB-500, and MOTS-c specifically, reviewers found no human clinical studies at all; for BPC-157, only a single small trial (a decades-old meeting abstract on ulcerative colitis), using none of the oral/subcutaneous/nasal/transdermal routes compounders actually use. The Committee’s own vote/discussion outcome from today has not yet been published — we’ll update this log with the actual recommendation once FDA or meeting coverage reports it. Day 2 (July 24: DSIP, Semax, Epitalon) has not happened yet.

2026-07-27Both days’ votes are in — the Committee went against FDA staff’s own recommendation on 6 of 7 peptides. Day 1 (July 23): BPC-157 and KPV passed 8-6 (1 abstention), TB-500 passed 8-6, and MOTS-c passed 7-5 (2 abstentions) — all four recommended FOR inclusion on the 503A Bulks List, despite FDA career scientists’ stated opposition citing insufficient safety/efficacy evidence. Day 2 (July 24): Semax passed 8-5, Epitalon passed 7-5 (1 abstention) — both recommended FOR inclusion. DSIP (Emideltide) was the only rejection, voted down 6-7 (1 abstention). Net result: 6 of 7 peptides recommended for the list, only DSIP rejected. This is still an advisory recommendation, not a final rule — FDA is not bound by it and has overridden PCAC recommendations before; a formal rulemaking process would still be required before any of these substances could actually be added to the 503A Bulks List. See “What This Does Not Mean (Yet)” below, which still applies.

At a Glance

Committee: FDA Pharmacy Compounding Advisory Committee (PCAC)
Meeting Dates: July 23-24, 2026
What's Being Decided: Whether each peptide qualifies for the 503A Bulk Drug Substances List
Compounds, Day 1: BPC-157, KPV, TB-500, MOTS-c
Compounds, Day 2: DSIP (emideltide), Semax, Epitalon
Prior Step: April 2026: FDA removed all seven from Category 2 of the Bulks List, making them eligible for this review
Current Legal Status: Unchanged until FDA acts on the committee's recommendation — see "What This Does Not Mean" below

What's Actually Happening

The Pharmacy Compounding Advisory Committee advises the FDA on which bulk drug substances 503A-licensed compounding pharmacies may use to prepare patient-specific compounded medications. Substances go through a formal nomination and review process before landing on — or being kept off — that list.

In April 2026, the FDA removed BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon from Category 2 of the Bulks List (the category reserved for substances with identified safety concerns significant enough to block nomination outright). That move didn't clear these compounds for compounding — it made them eligible to be formally nominated and reviewed, which is what's happening at this PCAC meeting.

Meeting Schedule

Day	Compounds Reviewed	Category
July 23, 2026	BPC-157, KPV, TB-500, MOTS-c	Tissue repair / metabolic research peptides
July 24, 2026	DSIP (emideltide), Semax, Epitalon	Sleep, cognitive, and longevity research peptides

What This Does Not Mean (Yet)

Not FDA approval. No peptide reviewed at this meeting is being evaluated as a new drug. 503A Bulks List eligibility is a separate, narrower question about compounding sourcing, not a drug-approval pathway.
Not a final ruling. The PCAC makes a recommendation to the FDA. The agency still has to act on that recommendation before anything changes for compounding pharmacies, prescribers, or research suppliers.
Not a ban, either. A negative recommendation on any individual compound would mean it stays off the 503A list — it does not retroactively restrict research use of material already lawfully obtained for in vitro or preclinical research.

Why This Matters for Research Peptide Access

If a compound is added to the 503A Bulks List, licensed compounding pharmacies gain a clear, FDA-recognized pathway to prepare patient-specific formulations of it. That's a meaningfully different sourcing channel than the research-use-only peptide market this site covers, but the outcome of this review will likely shape the broader regulatory conversation around several of the compounds referenced throughout our protocol library.

BPC-157 Protocol TB-500 Protocol KPV Protocol MOTS-c Protocol DSIP Protocol Semax Protocol Epitalon Protocol Regulatory Dashboard

Sources

This page will be updated as the meeting proceeds and as the FDA acts on the committee's recommendation. Check the update log above for the latest revision.

Frequently Asked Questions

Does FDA review mean BPC-157 and the other peptides are now approved for compounding?

No. Being reviewed by the PCAC is a step in the process, not a decision. The April 2026 removal from Category 2 made these peptides eligible for review — it did not clear them for compounding. The committee's recommendation from this meeting still requires FDA action before anything changes.

Which peptides are being reviewed?

Day one (July 23): BPC-157, KPV, TB-500, and MOTS-c. Day two (July 24): DSIP (also called emideltide), Semax, and Epitalon.

What is the 503A Bulk Drug Substances List?

It's the FDA list of bulk substances licensed 503A compounding pharmacies may use to prepare compounded medications for individual patients, outside the standard new-drug approval pathway. Whether a substance is on this list directly affects whether compounders can legally source and prepare it.